- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Seaport Therapeutics, Inc. Common Stock(SPTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SPTX
11/13/2026: SPTX (1-star) is currently NOT-A-BUY. Pass it for now.
Seaport Therapeutics is a clinical-stage biotechnology company focused on developing oral neuropsychiatric medicines for conditions like depression and anxiety. The company's primary strength lies in its proprietary Glyph platform, which aims to improve drug bioavailability and reduce side effects. Investors are drawn to its potential for high growth as it advances lead candidates like GlyphAllo through clinical trials. However, it faces significant risks as a pre-revenue company, including the inherent uncertainty of clinical development, the need for future funding, and stiff competition from established pharmaceutical players. It is best suited for growth-oriented investors with high risk tolerance who monitor upcoming clinical trial results closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is a clinical-stage biotech with high-growth potential linked to its proprietary technology platform. |
| Momentum investor | Strong fit while signal remains positive | The stock may attract momentum following positive clinical trial data announcements. |
| Value investor | Weak fit | The company is unprofitable and lacks the earnings history required for traditional value investing. |
| Dividend investor | Weak fit | The company does not pay dividends and is currently in a capital-intensive development phase. |
| Low-risk investor | Weak fit | The high volatility and clinical risk associated with biotech startups make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are highly sensitive to trial results and news flow. |
| Valuation risk | Medium / high | Valuations for pre-revenue biotech companies are often based on subjective probabilities of clinical success. |
| Competition risk (CNS drug development) | High | The company faces deep-pocketed competitors in the depression and anxiety drug markets. |
| Business quality | Medium | The company is an early-stage venture with unproven products. |
| Dividend income | Low / none | There is no income component to the investment. |
| Execution risk | High | Success depends heavily on achieving clinical trial endpoints and navigating regulatory approval. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio - | 1Y Target Price 37.12 |
Price to earnings Ratio - | 1Y Target Price 37.12 | ||
Volume (30-day avg) 242.7K shares | Beta - | 52 Weeks Range 14.85 - 28.38 | Updated Date 11/14/2026 |
52 Weeks Range 14.85 - 28.38 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.35 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical and preclinical development of Glyph-based oral therapeutics. | The company earns no revenue yet; it is investing capital to develop drugs that, if successful, will be sold to patients via pharmaceutical distribution channels. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 791.82M | Price to Sales(TTM) - |
Enterprise Value 791.82M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 53.53M | Shares Floating 18.43M |
Shares Outstanding 53.53M | Shares Floating 18.43M | ||
Percent Insiders 34.99 | Percent Institutions 73.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

